Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Lung Cancer Data May Offer Reprieve For Peregrine’s Bavituximab

This article was originally published in The Pink Sheet Daily

Executive Summary

Company releases new analysis of a Phase II second-line lung cancer study that resolves discrepancies that were holding back regulatory progress, now showing a 4.4 month overall survival benefit for first-in-class bavituximab. Peregrine is now gearing up for a Phase III study at the end of 2013.

Advertisement

Related Content

Peregrine Puts Positive Breast Cancer Trial Data Under Its Belt

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel